Pharmabiz1d
China NMPA grants breakthrough therapy designation for Innovent’s PD-1/IL-2a-bias bispecific antibody fusion protein, IBI363 in melanoma
China NMPA grants breakthrough therapy designation for Innovent’s PD-1/IL-2a-bias bispecific antibody fusion protein, IBI363 in melanoma: San Francisco, US Tuesday, April 1, 202 ...
J.P. Morgan Sticks to Their Buy Rating for Innovent Biologics (IVBXF)
In a report released on March 28, Yang Huang from J.P. Morgan maintained a Buy rating on Innovent Biologics (IVBXF – Research Report), with a ...
Innovent Receives NMPA Breakthrough Therapy Designation For IBI363 (PD-1/IL-2Α-Bias Bispecific Antibody Fusion Protein) In Melanoma
SAN FRANCISCO and SUZHOU, China, March 30, 2025 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutic ...
Leading Chinese Biotech Company Innovent Is on Track to Profitability
Innovent is a leading biotech company in China with strong roots in oncology, anchored by its core PD-1 drug Tyvyt. The price cut for PD-1 drugs has stabilized gradually. Hence, we expect stable ...
The Manila Times6d
Innovent to Present Preclinical Data of Multiple Novel Molecules at the 2025 AACR Annual Meeting
Innovent Biologics, Inc. ('Innovent') (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, ...